• Categories:Company
• Author:
• Origin:
• Time of issue:2022-05-28
• Views:0

(Summary description)


On March 25, 2022, China Medical Devices Co., Ltd. (hereinafter referred to as "Sinopharm Instrument") and Zhejiang Dongfang Gene Biological Products Co., Ltd. (hereinafter referred to as "Dongfang Bio") signed a strategic cooperation agreement in the form of an online contract. Zhang Wei, deputy general manager of Sinopharm Instruments, and Xu Faying, deputy general manager of Oriental Biological Sales, signed the contract on behalf of both parties. He Tao, President of Zhejiang Medical Device Industry Association, Li Jianfei, Assistant General Manager of Sinopharm, Hu Zhenyu, Deputy General Manager of the Western Division, Hu Pan, Director of Marketing, Yan Jipeng, Deputy Director, Zhao Hui, Executive Deputy General Manager and Deputy General Manager of Sinopharm Zhejiang Company Zhao Liang and Zhan Yao, Director of the General Manager's Office of Oriental Biology, attended the ceremony and witnessed the signing ceremony.

Oriental Bio was established in 2005 and listed on the Shanghai Stock Exchange's Science and Technology Innovation Board in 2020. It is an enterprise specializing in the production, sales and research of IVD in vitro diagnostic products. Its business fields cover molecular diagnostic platforms, POCT rapid diagnostic platforms, and liquid biochip platforms. On March 15, 2022, it became the first medical device enterprise in Zhejiang Province to obtain the registration certificate for the domestic novel coronavirus antigen detection kit.

Deputy General Manager Zhang Wei pointed out in the signing speech that with the signing of this strategic cooperation agreement, Sinopharm will give full play to the advantages of integrated marketing, and rely on the national network layout and logistics and information resources to deepen cooperation with Orient Bio in various aspects. Cooperation. At the same time, Sinopharm Instruments, as a national strategic reserve enterprise for medical devices, will jointly support the domestic new crown epidemic prevention and control needs through cooperation with Orient Bio in the new crown antigen detection kit. Deputy General Manager Xu Faying also expressed his willingness to share resources with Sinopharm and form a joint development force. President He Tao congratulated the two sides on the strategic cooperation and hoped that the two sides would make new contributions during the special period of epidemic prevention and control. In the future, Sinopharm Instruments and Orient Bio will build a nationwide professional supply chain channel to provide a full range of high-quality services for downstream distributors, terminal hospitals and more people.